驱动蛋白家族成员20A(KIF20A)的功能分析:一种潜在的胶质瘤免疫治疗靶点
研究通过蛋白质印迹和定量PCR分析发现,KIF20A在胶质瘤细胞系和胶质瘤组织中的表达高于正常脑组织;免疫染色显示KIF20A参与纺锤体形成和胞质分裂,尤其在分裂中的胶质瘤细胞高表达。癌症芯片数据库的计算机分析显示,KIF20A在胶质瘤中的高表达与病理分级相关,KIF20A高表达患者预后较差;下调KIF20A因胞质分裂失败和双核细胞生成而降低胶质瘤细胞增殖,抑制KIF20A在SF126胶质瘤细胞中诱导显著凋亡。作者认为KIF20A是参与胶质瘤细胞生长和存活的肿瘤相关抗原,是胶质瘤的癌抗原,也是胶质瘤新的免疫治疗候选靶点。
要点
- KIF20A在胶质瘤细胞系和胶质瘤组织中表达高于正常脑组织。
- KIF20A高表达与病理分级相关,KIF20A高表达患者预后较差。
- 下调KIF20A降低胶质瘤细胞增殖,抑制KIF20A在SF126细胞中诱导显著凋亡。
核心结论
- KIF20A是参与胶质瘤细胞生长和细胞存活的肿瘤相关抗原,是胶质瘤的癌抗原。
- KIF20A是胶质瘤新的免疫治疗候选靶点。
研究设计与样本
- 研究分析KIF20A在胶质瘤中的表达与功能,采用蛋白质印迹和定量PCR分析胶质瘤细胞系与胶质瘤组织,对胶质瘤细胞和胶质瘤组织进行KIF20A免疫染色,并对癌症芯片数据库进行计算机分析。
主要发现
- 蛋白质印迹和定量PCR分析显示,KIF20A在胶质瘤细胞系和胶质瘤组织中的表达高于正常脑组织。
- KIF20A免疫染色显示KIF20A参与纺锤体形成和胞质分裂,KIF20A高表达,尤其在分裂中的胶质瘤细胞。
- 癌症芯片数据库的计算机分析显示,KIF20A在胶质瘤中高表达且取决于病理分级,KIF20A高表达患者预后较差。
- 下调KIF20A因胞质分裂失败和双核细胞生成而降低胶质瘤细胞增殖。
- 抑制KIF20A在SF126胶质瘤细胞中诱导显著凋亡。
临床怎么用
- 作者认为KIF20A是胶质瘤新的免疫治疗候选靶点。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kinesin family member 20A (KIF20A), an ideal cancer-testis antigen, was reported to be a promising immunotherapeutic target for pancreatic cancers. Clinical trials of KIF20A peptide vaccine immunotherapy have been conducted against pancreatic cancers. To demonstrate the efficacy of KIF20A as a candidate molecular target for gliomas, we analyzed the expression and function of KIF20A in gliomas. Western blot and quantitative PCR analyses showed that KIF20A expression in glioma cell lines and glioma tissues was high compared with that found in a normal brain. KIF20A immunostaining of glioma cells and glioma tissues demonstrated that KIF20A was involved in spindle formation and cytokinesis, and that KIF20A was highly expressed, especially in glioma cells undergoing mitosis. In silico analysis of a cancer microarray database revealed that KIF20A was highly expressed in gliomas depending on the pathological grade, and glioma patients with higher expression of KIF20A showed poorer prognosis. Down-regulating KIF20A reduced cell proliferation in glioma cells due to the failure of cytokinesis and generation of binucleated cells. Additionally, KIF20A inhibition induced significant apoptosis in SF126 glioma cells. Taken together, KIF20A is a tumor-associated antigen involved in the glioma cell growth and cell survival, suggesting that KIF20A is an oncoantigen of gliomas. Thus, KIF20A is a candidate novel immunotherapeutic target for gliomas.
引用
- Saito K, Ohta S, Kawakami Y, et al. Functional analysis of KIF20A, a potential immunotherapeutic target for glioma. J Neurooncol. 2017. PMID: 28070829. doi:10.1007/s11060-016-2360-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。